Opthea Limited (OPT)
USD 3.41
(1.49%)
USD 3.41
(1.49%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 191.96 Million USD | -14.09% |
| 2023 | 150.13 Million USD | 55.37% |
| 2022 | 96.62 Million USD | 143.33% |
| 2021 | 39.71 Million USD | 133.32% |
| 2020 | 17.01 Million USD | -35.46% |
| 2019 | 26.36 Million USD | 13.89% |
| 2018 | 23.15 Million USD | 211.07% |
| 2017 | 7.44 Million USD | 26.99% |
| 2016 | 5.86 Million USD | -13.24% |
| 2015 | 6.75 Million USD | -2.52% |
| 2014 | 6.93 Million USD | 9.05% |
| 2013 | 6.35 Million USD | -29.4% |
| 2012 | 9 Million USD | -31.42% |
| 2011 | 13.12 Million USD | 79.51% |
| 2010 | 7.31 Million USD | 8.12% |
| 2009 | 6.76 Million USD | -14.74% |
| 2008 | 7.93 Million USD | -34.9% |
| 2007 | 12.18 Million USD | 365.7% |
| 2006 | 2.61 Million USD | 48.76% |
| 2005 | 1.75 Million USD | 39.17% |
| 2004 | 1.26 Million USD | -36.72% |
| 2003 | 1.99 Million USD | 167.53% |
| 2002 | 746.54 Thousand USD | 11284.38% |
| 2001 | 6557.61 USD | -97.9% |
| 2000 | 312.14 Thousand USD | -96.85% |
| 1999 | 9.89 Million USD | 122217.19% |
| 1998 | 8093.34 USD | 59.12% |
| 1997 | 5086.29 USD | -96.91% |
| 1996 | 164.67 Thousand USD | 70.33% |
| 1995 | 96.68 Thousand USD | 15.75% |
| 1994 | 83.52 Thousand USD | 66.48% |
| 1993 | 50.17 Thousand USD | 52.79% |
| 1992 | 32.83 Thousand USD | -37.26% |
| 1991 | 52.33 Thousand USD | 735.92% |
| 1990 | 6261.03 USD | 209.15% |
| 1989 | -5736.20 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 94.62 Million USD | 0.0% |
| 2024 FY | 192.7 Million USD | 28.36% |
| 2024 Q4 | 191.75 Million USD | 0.0% |
| 2023 FY | 150.13 Million USD | 55.37% |
| 2023 Q4 | 70.81 Million USD | 0.0% |
| 2023 Q2 | 78.9 Million USD | 0.0% |
| 2022 FY | 96.62 Million USD | 143.33% |
| 2022 Q4 | 58.52 Million USD | 0.0% |
| 2022 Q2 | 39.37 Million USD | 0.0% |
| 2021 FY | 39.71 Million USD | 133.32% |
| 2021 Q2 | 19.09 Million USD | 0.0% |
| 2021 Q4 | 21.86 Million USD | 0.0% |
| 2020 FY | 17.01 Million USD | -35.46% |
| 2020 Q4 | 8.98 Million USD | 0.0% |
| 2020 Q2 | 8.11 Million USD | 0.0% |
| 2019 FY | 26.36 Million USD | 13.89% |
| 2019 Q2 | 14.33 Million USD | 0.0% |
| 2019 Q4 | 12.08 Million USD | 0.0% |
| 2018 Q4 | 12.69 Million AUD | 0.0% |
| 2018 Q2 | 10.73 Million USD | 0.0% |
| 2018 FY | 23.15 Million USD | 211.07% |
| 2017 FY | 7.44 Million USD | 26.99% |
| 2017 Q4 | 3.59 Million AUD | 0.0% |
| 2017 Q2 | 3.6 Million USD | 0.0% |
| 2016 Q2 | 2.07 Million USD | 0.0% |
| 2016 FY | 5.86 Million USD | -13.24% |
| 2016 Q4 | 4.22 Million AUD | 0.0% |
| 2015 FY | 6.75 Million USD | -2.52% |
| 2015 Q4 | 3.26 Million AUD | 0.0% |
| 2015 Q2 | 3.7 Million USD | 0.0% |
| 2014 Q2 | 3.13 Million USD | 0.0% |
| 2014 Q4 | 3.62 Million AUD | 0.0% |
| 2014 FY | 6.93 Million USD | 9.05% |
| 2013 Q3 | 1.6 Million USD | -59.89% |
| 2013 FY | 6.35 Million USD | -29.4% |
| 2013 Q2 | 3.99 Million USD | 136.28% |
| 2013 Q1 | 1.69 Million USD | 0.0% |
| 2013 Q4 | 2.85 Million USD | 78.2% |
| 2012 FY | 9 Million USD | -31.42% |
| 2012 Q4 | - USD | -100.0% |
| 2012 Q3 | 1.69 Million USD | -1.92% |
| 2012 Q2 | 1.72 Million USD | -27.84% |
| 2012 Q1 | 2.38 Million USD | 0.0% |
| 2011 Q1 | -2.62 Million USD | 0.0% |
| 2011 Q3 | 2.53 Million USD | 3.95% |
| 2011 Q4 | - USD | -100.0% |
| 2011 FY | 13.12 Million USD | 79.51% |
| 2011 Q2 | 2.43 Million USD | 193.01% |
| 2010 Q3 | -2.48 Million USD | -3.18% |
| 2010 Q1 | -2.44 Million USD | 0.0% |
| 2010 FY | 7.31 Million USD | 8.12% |
| 2010 Q4 | - USD | 100.0% |
| 2010 Q2 | -2.41 Million USD | 1.17% |
| 2009 Q1 | 1.73 Million USD | 0.0% |
| 2009 Q3 | -1.94 Million USD | -7.22% |
| 2009 FY | 6.76 Million USD | -14.74% |
| 2009 Q4 | - USD | 100.0% |
| 2009 Q2 | -1.81 Million USD | -204.59% |
| 2008 Q3 | 2.06 Million USD | 2.02% |
| 2008 Q1 | 3.77 Million USD | 0.0% |
| 2008 Q2 | 2.02 Million USD | -46.4% |
| 2008 Q4 | - USD | -100.0% |
| 2008 FY | 7.93 Million USD | -34.9% |
| 2007 Q1 | -894.1 Thousand USD | 0.0% |
| 2007 Q4 | - USD | -100.0% |
| 2007 FY | 12.18 Million USD | 365.7% |
| 2007 Q2 | 3.31 Million USD | 470.28% |
| 2007 Q3 | 3.45 Million USD | 4.45% |
| 2006 FY | 2.61 Million USD | 48.76% |
| 2006 Q3 | -849.64 Thousand USD | 5.28% |
| 2006 Q2 | -896.98 Thousand USD | -254.99% |
| 2006 Q4 | - USD | 100.0% |
| 2006 Q1 | 578.75 Thousand USD | 0.0% |
| 2005 Q2 | 589.01 Thousand USD | 27.03% |
| 2005 Q3 | 586.73 Thousand USD | -0.39% |
| 2005 Q4 | - USD | -100.0% |
| 2005 FY | 1.75 Million USD | 39.17% |
| 2005 Q1 | 463.67 Thousand USD | 0.0% |
| 2004 Q3 | 487.75 Thousand USD | -0.93% |
| 2004 Q1 | -751.97 Thousand USD | 0.0% |
| 2004 Q4 | - USD | -100.0% |
| 2004 Q2 | 492.31 Thousand USD | 165.47% |
| 2004 FY | 1.26 Million USD | -36.72% |
| 2003 Q1 | 878.68 Thousand USD | 0.0% |
| 2003 Q2 | -647.15 Thousand USD | -173.65% |
| 2003 FY | 1.99 Million USD | 167.53% |
| 2003 Q3 | -661.12 Thousand USD | -2.16% |
| 2003 Q4 | - USD | 100.0% |
| 2002 Q1 | -191.23 Thousand USD | 0.0% |
| 2002 Q2 | 821.34 Thousand USD | 529.49% |
| 2002 Q4 | - USD | -100.0% |
| 2002 Q3 | 857.91 Thousand USD | 4.45% |
| 2002 FY | 746.54 Thousand USD | 11284.38% |
| 2001 Q2 | -213.96 Thousand USD | -163.97% |
| 2001 FY | 6557.61 USD | -97.9% |
| 2001 Q4 | - USD | 100.0% |
| 2001 Q3 | -190.48 Thousand USD | 10.97% |
| 2001 Q1 | 334.45 Thousand USD | 0.0% |
| 2000 FY | 312.14 Thousand USD | -96.85% |
| 2000 Q1 | 777.15 Thousand USD | 0.0% |
| 2000 Q4 | - USD | -100.0% |
| 2000 Q2 | 396.04 Thousand USD | -49.04% |
| 2000 Q3 | 373.82 Thousand USD | -5.61% |
| 1999 Q3 | 749.04 Thousand USD | 0.27% |
| 1999 Q1 | -294.52 Thousand USD | 3.65% |
| 1999 FY | 9.89 Million USD | 122217.19% |
| 1999 Q2 | 747.05 Thousand USD | 353.65% |
| 1999 Q4 | - USD | -100.0% |
| 1998 Q4 | -305.67 Thousand USD | 7.87% |
| 1998 Q2 | -336.66 Thousand USD | -7.96% |
| 1998 Q3 | -331.77 Thousand USD | 1.45% |
| 1998 Q1 | -311.85 Thousand USD | 0.0% |
| 1998 FY | 8093.34 USD | 59.12% |
| 1997 FY | 5086.29 USD | -96.91% |
| 1997 Q2 | -329.24 Thousand USD | -53.09% |
| 1997 Q1 | -215.06 Thousand USD | -0.2% |
| 1997 Q3 | -336.85 Thousand USD | -2.31% |
| 1997 Q4 | - USD | 100.0% |
| 1996 Q4 | -214.64 Thousand USD | -1.03% |
| 1996 Q1 | -124.9 Thousand USD | -5.73% |
| 1996 FY | 164.67 Thousand USD | 70.33% |
| 1996 Q2 | -204.15 Thousand USD | -63.45% |
| 1996 Q3 | -212.44 Thousand USD | -4.06% |
| 1995 Q3 | -120.96 Thousand USD | 4.55% |
| 1995 Q2 | -126.73 Thousand USD | -1042.35% |
| 1995 Q1 | -11.09 Thousand USD | -1.58% |
| 1995 FY | 96.68 Thousand USD | 15.75% |
| 1995 Q4 | -118.13 Thousand USD | 2.34% |
| 1994 Q4 | -10.92 Thousand USD | -3.49% |
| 1994 Q3 | -10.55 Thousand USD | 0.8% |
| 1994 Q2 | -10.63 Thousand USD | 87.1% |
| 1994 Q1 | -82.45 Thousand USD | 3.57% |
| 1994 FY | 83.52 Thousand USD | 66.48% |
| 1993 Q4 | -85.5 Thousand USD | 4.5% |
| 1993 FY | 50.17 Thousand USD | 52.79% |
| 1993 Q2 | -86.32 Thousand USD | -518.06% |
| 1993 Q1 | -13.96 Thousand USD | 3.88% |
| 1993 Q3 | -89.53 Thousand USD | -3.72% |
| 1992 FY | 32.83 Thousand USD | -37.26% |
| 1992 Q1 | -34.66 Thousand USD | -3.93% |
| 1992 Q4 | -14.52 Thousand USD | 2.63% |
| 1992 Q3 | -14.92 Thousand USD | -2.31% |
| 1992 Q2 | -14.58 Thousand USD | 57.93% |
| 1991 Q1 | -127.48 Thousand USD | -4.87% |
| 1991 Q3 | -33.68 Thousand USD | 1.11% |
| 1991 FY | 52.33 Thousand USD | 735.92% |
| 1991 Q4 | -33.35 Thousand USD | 0.99% |
| 1991 Q2 | -34.06 Thousand USD | 73.28% |
| 1990 Q3 | -115.76 Thousand USD | 2.34% |
| 1990 FY | 6261.03 USD | 209.15% |
| 1990 Q1 | -103.96 Thousand USD | -2.5% |
| 1990 Q2 | -118.53 Thousand USD | -14.02% |
| 1990 Q4 | -121.55 Thousand USD | -5.0% |
| 1989 Q3 | -109.31 Thousand USD | 6.81% |
| 1989 Q4 | -101.42 Thousand USD | 7.21% |
| 1989 Q2 | -117.3 Thousand USD | 0.0% |
| 1989 FY | -5736.20 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 150.53 Million USD | -27.523% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -2751.589% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -551.421% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -278.686% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -14.384% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -20.14% |
| Agenus Inc. | 78.18 Million USD | -145.536% |
| Fortress Biotech, Inc. | 200.19 Million USD | 4.11% |
| GlycoMimetics, Inc. | 39.28 Million USD | -388.65% |
| Novavax, Inc. | 779.12 Million USD | 75.361% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -13.404% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -762.659% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -98.498% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -45.237% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 4.548% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 89.336% |
| AlloVir, Inc. | 180.93 Million USD | -6.099% |
| Aptorum Group Limited | 10.56 Thousand USD | -1816740.801% |
| Ardelyx, Inc. | 169.93 Million USD | -12.964% |
| Bicycle Therapeutics plc | 216.92 Million USD | 11.504% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -11.673% |
| Chimerix, Inc. | 93.38 Million USD | -105.557% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1280.103% |
| CRISPR Therapeutics AG | 463.49 Million USD | 58.583% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -486.787% |
| Precision BioSciences, Inc. | 92.46 Million USD | -107.615% |
| Dyadic International, Inc. | 9.15 Million USD | -1997.386% |
| Elevation Oncology, Inc. | 45.44 Million USD | -322.417% |
| Fortress Biotech, Inc. | 200.19 Million USD | 4.11% |
| GT Biopharma, Inc. | 13.57 Million USD | -1314.02% |
| Alkermes plc | 996.24 Million USD | 80.731% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1089.307% |
| Innoviva, Inc. | 132.15 Million USD | -45.26% |
| IO Biotech, Inc. | 91.44 Million USD | -109.931% |
| Jaguar Health, Inc. | 42.01 Million USD | -356.902% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -127.657% |
| ContextLogic Inc. | 387 Million USD | 50.396% |
| AbCellera Biologics Inc. | 275.23 Million USD | 30.253% |
| Lantern Pharma Inc. | 17.87 Million USD | -973.789% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2171.535% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 56.933% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 49.548% |
| MEI Pharma, Inc. | 34.78 Million USD | -451.868% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -126.601% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -689.775% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -19.576% |
| NextCure, Inc. | 67.63 Million USD | -183.82% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -486.232% |
| ChromaDex Corporation | 56.37 Million USD | -240.495% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -21.642% |
| Incyte Corporation | 1.19 Billion USD | 83.875% |
| MiMedx Group, Inc. | 229.72 Million USD | 16.437% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -261.341% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -105.361% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -6876.612% |
| Vaxcyte, Inc. | 468.04 Million USD | 58.985% |
| PDS Biotechnology Corporation | 43.04 Million USD | -345.967% |
| Pharming Group N.V. | 225.49 Million USD | 14.867% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -164.542% |
| Onconetix, Inc. | 34.9 Million USD | -449.933% |
| Acelyrin, Inc. | 422.06 Million USD | 54.517% |
| PureTech Health plc | 144.59 Million USD | -32.76% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -133.548% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 21.696% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -888.579% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -689.775% |
| ESSA Pharma Inc. | 32.13 Million USD | -497.395% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -47.369% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -548.407% |
| Seer, Inc. | 110.49 Million USD | -73.742% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 16.054% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -406.925% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -522.079% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1488711.843% |
| Summit Therapeutics Inc. | 87.68 Million USD | -118.926% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -417.935% |
| Senti Biosciences, Inc. | 94.7 Million USD | -102.7% |
| ImmuCell Corporation | 9.61 Million USD | -1896.05% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -523.858% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -136.816% |
| Precigen, Inc. | 84.18 Million USD | -128.041% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -238.215% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1406.099% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -55.373% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -13.971% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -4769.738% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 52.432% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -171.932% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -463.202% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -546.747% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -999.659% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -5.883% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 24.435% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -914.144% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 12.675% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 26.003% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -254.969% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -1831.719% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 26.069% |
| Aptose Biosciences Inc. | 52.35 Million USD | -266.658% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1232.147% |
| Soligenix, Inc. | 7.79 Million USD | -2362.62% |
| Century Therapeutics, Inc. | 56.07 Million USD | -242.365% |
| Kura Oncology, Inc. | 165.8 Million USD | -15.78% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -67.647% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2207.578% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -7635.509% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -78.246% |
| Autolus Therapeutics plc | 196.72 Million USD | 2.419% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -126.759% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -64.845% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -890.391% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 40.338% |
| GRI Bio, Inc. | 11.33 Million USD | -1594.328% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -2620.742% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -46.324% |
| IGM Biosciences, Inc. | 265.59 Million USD | 27.721% |
| INmune Bio, Inc. | 29.89 Million USD | -542.117% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -11.251% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -376.177% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1101.346% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1119.495% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -209.136% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -78.538% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 30.369% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 36.319% |
| Verastem, Inc. | 92.08 Million USD | -108.47% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -970.112% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -3.361% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -58.119% |
| Histogen Inc. | 14.27 Million USD | -1245.063% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1096.197% |
| Surrozen, Inc. | 18.55 Million USD | -934.865% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1187.076% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3671.287% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -221.698% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -648.498% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -308.389% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2415.018% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -7.765% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -296.234% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 21.647% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1149.253% |
| Apollomics, Inc. | 54.14 Million USD | -254.576% |
| Amarin Corporation plc | 272.35 Million USD | 29.516% |
| Mesoblast Limited | 5.9 Million USD | -3152.582% |
| Turnstone Biologics Corp. | 78.33 Million USD | -145.05% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 21.364% |
| Synaptogenix, Inc. | 8.31 Million USD | -2209.006% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1216.107% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 24.14% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -475.958% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2073.732% |
| Exelixis, Inc. | 1.58 Billion USD | 87.902% |
| Better Therapeutics, Inc. | 38.26 Million USD | -401.718% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 17.273% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 77.553% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1525.869% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2287.088% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -540.041% |
| Gritstone bio, Inc. | 148.37 Million USD | -29.381% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -178.775% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1073.379% |
| Avid Bioservices, Inc. | 25.99 Million USD | -638.45% |
| Insmed Incorporated | 949.26 Million USD | 79.777% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1123.518% |
| MediWound Ltd. | 18.86 Million USD | -917.423% |
| OmniAb, Inc. | 83.89 Million USD | -128.819% |
| Alector, Inc. | 248.8 Million USD | 22.843% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 18.07% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -267.395% |
| Zai Lab Limited | 547.47 Million USD | 64.936% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 51.846% |
| Aura Biosciences, Inc. | 84.99 Million USD | -125.868% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 22.324% |
| Immunic, Inc. | 99.22 Million USD | -93.471% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -20.725% |
| Veracyte, Inc. | 357.93 Million USD | 46.368% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.871% |
| FibroGen, Inc. | 398.11 Million USD | 51.781% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1250.932% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -2687.005% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -2594.003% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 94.104% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -641.96% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 39.355% |
| TG Therapeutics, Inc. | 198.47 Million USD | 3.279% |
| Galecto, Inc. | 35.62 Million USD | -438.826% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -371.792% |
| Fortrea Holdings Inc. | 457.3 Million USD | 58.022% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -253.674% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -564.753% |
| XBiotech Inc. | 37.51 Million USD | -411.777% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -178.775% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -829.669% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -35.13% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -93.76% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -73.387% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 79.967% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -565.514% |
| Vaxxinity, Inc. | 56.05 Million USD | -242.487% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 55.423% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -760.52% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -73.151% |
| NexImmune, Inc. | 28.16 Million USD | -581.521% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -3370.787% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -972.892% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 93.181% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -654.026% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1538.663% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -51.082% |
| Ainos, Inc. | 12.95 Million USD | -1382.069% |
| Pluri Inc. | 22.48 Million USD | -753.948% |
| Prothena Corporation plc | 282.4 Million USD | 32.024% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 4.027% |
| Celularity Inc. | 215.05 Million USD | 10.737% |
| Rallybio Corporation | 78.93 Million USD | -143.206% |
| Cue Biopharma, Inc. | 19.54 Million USD | -882.332% |
| MeiraGTx Holdings plc | 151.07 Million USD | -27.065% |
| Omeros Corporation | 94.75 Million USD | -102.602% |
| Humacyte, Inc. | 23.49 Million USD | -716.987% |
| Immunocore Holdings plc | 308.04 Million USD | 37.681% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -5562.755% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -120.995% |
| Blueprint Medicines Corporation | 722.86 Million USD | 73.443% |
| CalciMedica, Inc. | 21.81 Million USD | -779.898% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -157.122% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -12.068% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 34.913% |
| Pulmatrix, Inc. | 22.03 Million USD | -771.075% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -455.22% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -116.019% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 65.196% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -164.596% |
| Cytokinetics, Incorporated | 173.61 Million USD | -10.573% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -457.737% |
| Nutriband Inc. | 5.73 Million USD | -3247.861% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -340.161% |
| Vor Biopharma Inc. | 126.03 Million USD | -52.312% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 83.857% |
| Evogene Ltd. | 27.79 Million USD | -590.779% |
| ProKidney Corp. | 151.52 Million USD | -26.693% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -158.803% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2395.597% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 68.747% |
| CorMedix Inc. | 48.95 Million USD | -292.108% |
| BioLineRx Ltd. | 50.8 Million USD | -277.874% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -27.384% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -404.222% |
| Atai Life Sciences N.V. | 125.78 Million USD | -52.615% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -135.141% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -135.806% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 23.989% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -486.339% |
| MediciNova, Inc. | 10.9 Million USD | -1661.126% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -49.02% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2544.352% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3087.677% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 59.701% |
| Biomea Fusion, Inc. | 126.13 Million USD | -52.192% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 85.367% |
| Mereo BioPharma Group plc | 35.84 Million USD | -435.593% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -0.46% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 16.519% |
| Absci Corporation | 73.66 Million USD | -160.592% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -595.988% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -43.699% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 20.728% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 26.743% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 7.705% |
| Allakos Inc. | 196.05 Million USD | 2.085% |
| Imunon, Inc. | 20.31 Million USD | -845.167% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -69.18% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 47.922% |
| BioAtla, Inc. | 129.68 Million USD | -48.024% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1525.869% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1111.686% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -126.062% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -359.714% |
| XOMA Corporation | 46.46 Million USD | -313.162% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -72.678% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -34.749% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1379.062% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -85.197% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -11.047% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 24.649% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -413.172% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2234.003% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1042.255% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -8341.949% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 35.865% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2752.951% |
| UroGen Pharma Ltd. | 138.88 Million USD | -38.217% |
| Sutro Biopharma, Inc. | 243 Million USD | 21.004% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -2538.864% |
| Orgenesis Inc. | 45.75 Million USD | -319.537% |
| Entera Bio Ltd. | 8.86 Million USD | -2066.675% |
| GH Research PLC | 41.22 Million USD | -365.692% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -646.722% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -131.138% |
| Xencor, Inc. | 306.97 Million USD | 37.465% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -3791.016% |
| Replimune Group, Inc. | 234.77 Million USD | 18.233% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -836.888% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -0.089% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2752.951% |
| Portage Biotech Inc. | 18.19 Million USD | -954.824% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2544.352% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -82.894% |
| OncoCyte Corporation | 25.63 Million USD | -648.79% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3049.275% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1575.538% |
| Purple Biotech Ltd. | -22.46 Million USD | 954.442% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1064.851% |
| scPharmaceuticals Inc. | 65.17 Million USD | -194.528% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2171.068% |
| HilleVax, Inc. | 133.34 Million USD | -43.963% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -1766.479% |
| Tharimmune, Inc. | 9.45 Million USD | -1930.28% |
| Genprex, Inc. | 31.06 Million USD | -518.042% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -2.368% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -511.809% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -24993.778% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -3424.33% |
| OKYO Pharma Limited | 8243.57 USD | -2328592.532% |
| Savara Inc. | 15.74 Million USD | -1119.228% |
| Curis, Inc. | 58.35 Million USD | -228.965% |
| Daré Bioscience, Inc. | 33.6 Million USD | -471.172% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -3669.619% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2472.945% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -610.412% |
| BeiGene, Ltd. | 3.28 Billion USD | 94.159% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -862.759% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 61.511% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -24.936% |
| Erasca, Inc. | 141.52 Million USD | -35.642% |
| bluebird bio, Inc. | 240.23 Million USD | 20.091% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4140.524% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 89.007% |
| DBV Technologies S.A. | 92.16 Million USD | -108.298% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4140.524% |
| Moderna, Inc. | 6.39 Billion USD | 96.998% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -350.533% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1236.262% |
| Molecular Templates, Inc. | 63.09 Million USD | -204.271% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -187.803% |
| Travere Therapeutics, Inc. | 472 Million USD | 59.329% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -33.952% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -209.216% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -342.179% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 7.766% |
| MacroGenics, Inc. | 217.21 Million USD | 11.623% |
| RenovoRx, Inc. | 11.39 Million USD | -1584.516% |
| Adicet Bio, Inc. | 152.03 Million USD | -26.263% |
| Prime Medicine, Inc. | 186.63 Million USD | -2.855% |
| Aditxt, Inc. | 25.95 Million USD | -639.737% |
| Adagene Inc. | 41.83 Million USD | -358.908% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2526.058% |
| Quantum-Si incorporated | 111.65 Million USD | -71.923% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -11.706% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1216.85% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -435.892% |
| SciSparc Ltd. | 9.01 Million USD | -2030.367% |
| Vericel Corporation | 142.04 Million USD | -35.15% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2117.568% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -731.438% |
| Generation Bio Co. | 144.46 Million USD | -32.88% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -131.202% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -122.03% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 35.085% |
| Invivyd, Inc. | 205.75 Million USD | 6.701% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -166.034% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -1946.887% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -155.093% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -1766.116% |
| 2seventy bio, Inc. | 289.88 Million USD | 33.779% |
| ADMA Biologics, Inc. | 66.58 Million USD | -188.3% |
| Clene Inc. | 41.07 Million USD | -367.381% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1398.822% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -250.331% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3087.677% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 45.471% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -422.616% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -469.163% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -85.114% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -489.056% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -12.738% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 74.995% |
| Evaxion Biotech A/S | 22.27 Million USD | -762.0% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -41.627% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 18.271% |
| Trevena, Inc. | 38.41 Million USD | -399.746% |
| Surrozen, Inc. | 18.55 Million USD | -934.865% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -140.124% |
| Cingulate Inc. | 22.75 Million USD | -743.472% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 2662.298% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -329.775% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2231.416% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -87.179% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 74.543% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -209.256% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2096.084% |
| Kronos Bio, Inc. | 128.11 Million USD | -49.836% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -128.337% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -6445.12% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -90.393% |
| Statera Biopharma, Inc. | 28.82 Million USD | -565.871% |
| ImmunityBio, Inc. | 362.87 Million USD | 47.098% |
| Korro Bio, Inc. | 84.53 Million USD | -127.089% |
| Kineta, Inc. | 21.15 Million USD | -807.39% |
| BioVie Inc. | 31.95 Million USD | -500.833% |
| Codexis, Inc. | 66.51 Million USD | -188.595% |
| Celularity Inc. | 215.05 Million USD | 10.737% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 15.291% |
| Celcuity Inc. | 66.23 Million USD | -189.848% |
| Virax Biolabs Group Limited | 6.54 Million USD | -2832.115% |
| Cibus, Inc. | 320.3 Million USD | 40.067% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -346.436% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -467.213% |
| IN8bio, Inc. | 30.33 Million USD | -532.783% |
| Kodiak Sciences Inc. | 277.32 Million USD | 30.778% |
| Annexon, Inc. | 143.72 Million USD | -33.568% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -50.455% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -737.956% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -29894.906% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 75.376% |
| Eyenovia, Inc. | 25.4 Million USD | -655.585% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -36.812% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3351.41% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -142.588% |
| Arcellx, Inc. | 200.19 Million USD | 4.112% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -318.23% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 11.295% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -1827.964% |
| Moolec Science SA | 52.75 Million USD | -263.915% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -213.99% |
| Geron Corporation | 70.44 Million USD | -172.522% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -312.478% |
| Royalty Pharma plc | 862.4 Million USD | 77.74% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -104.064% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -1957.999% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -748.342% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 7.624% |
| Humacyte, Inc. | 23.49 Million USD | -716.987% |
| Structure Therapeutics Inc. | 102.77 Million USD | -86.784% |
| 89bio, Inc. | 151.2 Million USD | -26.959% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -139.564% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1220.271% |
| Genelux Corporation | 24.33 Million USD | -688.853% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -465.892% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -11.048% |
| Notable Labs, Ltd. | 14.77 Million USD | -1199.712% |
| Liquidia Corporation | 87.98 Million USD | -118.184% |
| Mustang Bio, Inc. | 48.5 Million USD | -295.801% |
| Immunovant, Inc. | 282.7 Million USD | 32.097% |
| Quantum-Si incorporated | 111.65 Million USD | -71.923% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -751.523% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -802.654% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -88.181% |
| Acasti Pharma Inc. | 11.3 Million USD | -1598.676% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -737.514% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1101.346% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -312.461% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -16819.688% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1108.406% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -558.392% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -363.869% |
| PepGen Inc. | 84.76 Million USD | -126.467% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -547.86% |
| United Therapeutics Corporation | 885.1 Million USD | 78.311% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -738.395% |
| Solid Biosciences Inc. | 104.31 Million USD | -84.027% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -486.598% |
| Immuneering Corporation | 58.41 Million USD | -228.639% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3671.287% |
| Silo Pharma, Inc. | 3.92 Million USD | -4794.81% |
| Belite Bio, Inc | 31.66 Million USD | -506.187% |
| XOMA Corporation | 46.46 Million USD | -313.162% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -184.186% |
| Bionomics Limited | 17.89 Billion USD | 98.927% |
| Apogee Therapeutics, Inc. | 93 Million USD | -106.41% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 638.025% |
| uniQure N.V. | 285.08 Million USD | 32.663% |
| Cassava Sciences, Inc. | 105.95 Million USD | -81.175% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2526.058% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 1.153% |
| Forte Biosciences, Inc. | 32.47 Million USD | -491.087% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2210.423% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -553.061% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3351.41% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1250.932% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2059.606% |
| Altimmune, Inc. | 30.55 Million USD | -528.248% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 55.111% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 638.025% |
| Compugen Ltd. | 43.97 Million USD | -336.577% |
| Peak Bio, Inc. | 1249.13 USD | -15367988.109% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -158.995% |
| Benitec Biopharma Inc. | 22.38 Million USD | -757.687% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 21.062% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -572.555% |
| Zura Bio Limited | 62.63 Million USD | -206.471% |
| PolyPid Ltd. | 21.04 Million USD | -812.176% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1079.451% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -572.555% |
| Instil Bio, Inc. | 85.78 Million USD | -123.777% |
| argenx SE | 1.53 Billion USD | 87.482% |
| Immunome, Inc. | 122.82 Million USD | -56.3% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -296.03% |
| Verona Pharma plc | 67.15 Million USD | -185.873% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -641.616% |
| Shattuck Labs, Inc. | 93.61 Million USD | -105.063% |
| CervoMed Inc. | 14.95 Million USD | -1183.396% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -171.512% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2146.809% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -276.407% |
| Moolec Science SA | 52.75 Million USD | -263.915% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1067.086% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -44.821% |
| AnaptysBio, Inc. | 181.56 Million USD | -5.728% |
| Design Therapeutics, Inc. | 78.19 Million USD | -145.514% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -120.548% |
| NeurAxis, Inc. | 8.82 Million USD | -2076.205% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1425.367% |
| Lumos Pharma, Inc. | 38.66 Million USD | -396.489% |
| Achilles Therapeutics plc | 75.25 Million USD | -155.089% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -641.616% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1324.355% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -624.339% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -6445.12% |
| Nutriband Inc. | 5.73 Million USD | -3247.861% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -73.287% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -244.936% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -277.302% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -190.424% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -254.687% |
| Palisade Bio, Inc. | 13.32 Million USD | -1341.197% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -322.752% |
| Beam Therapeutics Inc. | 554.19 Million USD | 65.361% |
| Neurogene Inc. | 55.58 Million USD | -245.371% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 22.746% |
| AEON Biopharma, Inc. | 48.42 Million USD | -296.389% |
| Sesen Bio, Inc. | 78.38 Million USD | -144.916% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -129.821% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1425.137% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 57.435% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -118.418% |
| Athira Pharma, Inc. | 125.46 Million USD | -53.004% |
| Vaccinex, Inc. | 23.45 Million USD | -718.45% |
| HCW Biologics Inc. | 21.02 Million USD | -812.934% |
| XOMA Corporation | 46.46 Million USD | -313.162% |
| Nektar Therapeutics | 190.9 Million USD | -0.558% |
| Arvinas, Inc. | 480 Million USD | 60.007% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -8341.949% |
| Merus N.V. | 200.49 Million USD | 4.253% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -85.736% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -454.499% |
| Rezolute, Inc. | 70.38 Million USD | -172.731% |
| Clene Inc. | 41.07 Million USD | -367.381% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1072.071% |
| BeyondSpring Inc. | 24.86 Million USD | -672.039% |
| Synlogic, Inc. | 58.53 Million USD | -227.97% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -972.923% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -4173.54% |
| Peak Bio, Inc. | 1249.13 USD | -15367988.109% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -217.585% |
| Krystal Biotech, Inc. | 160.42 Million USD | -19.661% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 29.067% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 44.843% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -8800.838% |
| MannKind Corporation | 125.59 Million USD | -52.844% |
| Ikena Oncology, Inc. | 84.57 Million USD | -126.974% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -1889.918% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -114.247% |
| Gossamer Bio, Inc. | 183.75 Million USD | -4.467% |
| CohBar, Inc. | 12.38 Million USD | -1449.587% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -278.455% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -595.988% |
| Legend Biotech Corporation | 583.14 Million USD | 67.081% |
| Mural Oncology plc | 192.07 Million USD | 0.054% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -185.891% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1089.001% |
| Disc Medicine, Inc. | 91.12 Million USD | -110.664% |
| Champions Oncology, Inc. | 28.11 Million USD | -582.915% |
| REGENXBIO Inc. | 321.15 Million USD | 40.226% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -3480.657% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -244.299% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -392.721% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -67.867% |
| Vaxart, Inc. | 90.72 Million USD | -111.59% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2153.136% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -348.584% |
| Cellectis S.A. | 97.32 Million USD | -97.254% |
| Longeveron Inc. | 21.25 Million USD | -803.376% |
| Repare Therapeutics Inc. | 167.35 Million USD | -14.705% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 85.893% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -153.774% |
| Revolution Medicines, Inc. | 498.76 Million USD | 61.511% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -2785.86% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -336.746% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -157.363% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -175.677% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1635.691% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.98% |
| Denali Therapeutics Inc. | 527.23 Million USD | 63.589% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2117.568% |
| Veru Inc. | 101.34 Million USD | -89.414% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -720.128% |
| Cingulate Inc. | 22.75 Million USD | -743.472% |
| Passage Bio, Inc. | 108.38 Million USD | -77.11% |
| Context Therapeutics Inc. | 25.07 Million USD | -665.646% |
| Exicure, Inc. | 14.07 Million USD | -1263.792% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 6.841% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -343.332% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -1991.766% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 23.968% |
| Nuvalent, Inc. | 149.49 Million USD | -28.413% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2279.692% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -85.207% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -794.995% |
| OmniAb, Inc. | 83.89 Million USD | -128.819% |
| Anew Medical, Inc. | 1.3 Million USD | -14657.176% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -485.91% |
| Lipocine Inc. | 15.08 Million USD | -1172.982% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -180.191% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -152.085% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -376.177% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -67.156% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -757.61% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 71.096% |
| Ocugen, Inc. | 71.56 Million USD | -168.235% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -104.512% |
| Q32 Bio Inc. | 92.68 Million USD | -107.129% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -806.618% |
| Alumis Inc. Common Stock | 158.17 Million USD | -21.365% |
| Equillium, Inc. | 50.6 Million USD | -279.337% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -207.61% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1280.509% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -917.579% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -308.868% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -76.984% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1449.033% |
| Dominari Holdings Inc. | 23.83 Million USD | -705.401% |
| Edesa Biotech, Inc. | 9.22 Million USD | -1981.453% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1512.223% |
| Bio-Techne Corporation | 563.03 Million USD | 65.905% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 53.042% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 28.572% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -45.125% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1232.089% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -17.271% |
| Nkarta, Inc. | 131.65 Million USD | -45.816% |
| BioCardia, Inc. | 12.12 Million USD | -1483.759% |
| Iterum Therapeutics plc | 47.46 Million USD | -304.414% |